Merck

Viral Vector Upstream Processing

Bioreactor graphic representing viral vector production

Optimizing the upstream portion of the gene therapy production workflow sets the stage for successful manufacturing by maximizing viral vector titers. Without the benefit of a proven template, however, process development teams must evaluate all aspects of viral vector production including:

To minimize variability and risk across these process inputs, gene therapy manufacturers can collaborate with an experienced technology partner with expertise in all aspects of viral vector production as well as related products and services.


Related Technical Articles

Find More Articles and Protocols


Thaw and Expand Cells and Seeds

Frozen cells from a working or master cell bank are thawed and expanded to increase their numbers in preparation for subsequent processing steps.

Media and Inoculum Prep

Cell culture media are optimized with the appropriate nutrients, supplements, and pH for cell growth and virus production.

Cell Growth and Virus Production

Cells are grown in a bioreactor or other controlled environment under specific conditions to maximize virus production.

Cell Lysis

In AAV production, host cells are lysed by chemical or mechanical means so that the viruses can be released into the media.

DNA Digestion

Unwanted whole cell and plasmid DNA is digested using a nuclease enzyme.


Related Technical Resources


Related Videos

Video image llustration of bottles filled with a substance on a yellow background
Efficient DNA Clearance

Benzonase® nuclease efficiently digests DNA and RNA into fragments smaller than 5 base pairs.

Illustration of medical professional, child, and caretaker, medical professional using stethoscope on child
Sf-RVN® Platform

For improving the safety profile of your gene therapy and vaccines.

Illustration of person in a lab coat gesturing to a large pink virus model
Draw on our Gene Therapy Experience

From scale-up to overcoming regulatory hurdles and zipping through production.

Beginning frame of video with words "Start Right to Scale Right, Gene Therapy Manufacturing"
Start Right to Scale Right

Successfully scale your gene therapy production by implementing a platform process from the start.


Related Webinars

Open laptop, screen shows a simplified image of a person and a pink rectangle on a yellow background.
Driving the Viral Vector Expressway: Speeding Through AAV Manufacturing

The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.


Workflow

 Illustration of a healthcare professional holding a large model of a virus, explaining it to a family of three against a yellow background

Gene Therapy Manufacturing

The rise of gene therapies is driving rapid innovation, but manufacturers face complex challenges bringing new therapies to life

Outlined illustration of a bioreactor depicted in purple against a white background.

Efficient virus purification processes can improve yield, decrease time to patient, and lower manufacturing costs

A purple line drawing of a chemistry flask connected to a condenser, depicted against a white background.

Formulating a commercially viable gene therapy demands a high level of application and regulatory expertise

Magnifying glass focusing on a virus structure, symbolizing analysis or inspection of viral components.

Critical biosafety testing and characterization of viral vector products can help mitigate safety concerns and increase product understanding

Purple line drawing of three bottles on a conveyor belt, with the middle bottle being filled by a machine.

CDMO partnerships play a critical role in advancing clinical pipelines and achieving successful commercialization




Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?